Article Details
Retrieved on: 2024-12-08 18:51:57
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Beam Therapeutics' innovative product strategy for treating sickle cell disease and beta thalassemia using the ESCAPE platform. It highlights their use of genetic engineering, particularly gene therapy, to improve fetal hemoglobin levels. Tags reflect Beam's focus, technologies, and conditions addressed.
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here